Fiona Simpkins, M.D.

faculty photo
Associate Professor of Obstetrics and Gynecology at the Hospital of the University of Pennsylvania
Department: Obstetrics and Gynecology

Contact information
Jordan Center for Gynecologic Oncology at Penn Perelman Center for Advanced Medicine
3400 Civic Center Blvd., 3rd Floor West
Philadelphia, PA 19104
Office: 215-662-3318
Fax: 215-349-5849
Education:
B.S (Biology)
University of California, Los Angeles, CA, 1993.
(Clinical Research Training Award)
University of California, Los Angeles, CA, 1995.
M.D.
Temple University School of Medicine, Philadelphia, PA, 1999.
(Molecular Signaling Section, Cancer Research Training Fellowship)
NIH, NCI, 2005.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Selected Publications

Cadoo K, Simpkins F, Mathews C, Kabil N, Bennett J, Aghajanian C.: Olaparib treatment in patients with platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study. ASCO (Virtual) Jun 2020.

Kim H, Xu, H, George E, Hallberg D, Kumar s, Jagannathan V, Medvedev S, Kinose Y, Devins K, Verma P, Ly K, Wang Y, Greenbure RA, Schwartz L, Johnson N, Scharpf R, Mills G, Zhang R, Velculesco V, Brown E, Simpkins F.: Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models. June, 2020 in press. Nature Communications Jun 2020.

Lin LL, Lakomy DS, Ning MS, Simpkins F, Jhingran A.: Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin. Int J Gynecol Cancer. Page: 30(4):409-423, Apr 2020.

Rodriguez-Garcia A, Sharma P, Poussin M, Boesteanu AC, Minutolo NG, Gitto SB, Omran DK, Robinson MK, Adams GP, Simpkins F, Powell DJ Jr. : CAR T Cells Targeting MISIIR for the Treatment of Ovarian Cancer and Other Gynecologic Malignancies. Mol Ther. Page: 28(2):548-560, Feb 2020.

Nasioudis D, Latif NA, Simpkins F, Cory L, Giuntoli RL 2nd, Haggerty AF, Morgan MA, Ko EM. : Adjuvant chemotherapy for early stage endometrioid ovarian carcinoma: An analysis of the National Cancer Data Base. Gynecol Oncol. Page: 156(2):315-319, Feb 2020.

Gitto SB, Kim H, Rafail S, Omran DK, Medvedev S, Kinose Y, Rodriguez-Garcia A, Flowers AJ, Xu H, Schwartz LE, Powell DJ Jr, Simpkins F.: An autologous humanized patient-derived-xenograft platform to evaluate immunotherapy in ovarian cancer. Gynecol Oncol. Page: 156(1):222-232, Jan 2020.

Kinose Y, Kim H, Xu H, Medvedev S, George E, Gitto S, Whicker M, Hallberg D, Schwartz L, Mills G, Velculescu VE, Wang T, Drapkin R, Simpkins F. : Dual blockade of BRD4 and the ATR/WEE1 pathway exploits ARID1A loss in clear-cell ovarian cancers AACR Advances in Ovarian Cancer Research Meeting, Atlanta, GA, Sept, 2019. AACR Advances in Ovarian Cancer Research Meeting, Atlanta, GA, Sept 2019.

Hyoung Kim, Veena Jagnnathan, Dorothy Halberg, Haineng Xu, Erin George, Sergey Medvedev, Yasuto Kinose, Anne van Harten, Victor Velculesco, Eric Brown, Fiona Simpkins: Optimizing DDRi combinations by genetic context in ovarian cancers from germline BRCA carriers. Basser Symposium for BRCA May 2019.

Arlene Garcia, Natalie MacKenzie, Margaret Whicker, Joseph Lucci, Matt Pearson, Loraine Portelance, Gordon Mills, Lilie Lin, Fiona Simpkins: Phase I clinical trial of nelfinavir and chemoradiation in locally advanced cervix cancer. SGO, Honolulu, HI Mar 2019.

*Simpkins F, Jang K, Yoon H, Hew K, Kim M, Azzam D, Sun J, Zhao D, Ince, T, Liu W, Guo W, Zhi Wei, Zhang G, Mills G, *Slingerland JM: *Co-corresponding authors. Dual Src and MEK inhibition decreases ovarian cancer growth and targets tumor initiating stem-like cells. Clin Cancer Res Oct 2018.

back to top
Last updated: 06/22/2020
The Trustees of the University of Pennsylvania